MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell LunG CanceR ImmunoTherapy) was the largest ever phase III lung cancer adjuvant trial that aimed in determining the efficiency of MAGE-A3 vaccine as an adjuvant therapy following tumor resection in MAGE-A3 positive stage IB, II, and IIIA NSCLC (37). This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.